Andrew Holland, CEO of Ambit Investment Advisors, says value has emerged in pharma sector in a month or so after FDA inspections and rulings. Pharms stocks are ripe for re-rating and within that re-rating there will be a switch back to the pharma sector from IT sector, added Mr Holland.